The standard treatment duration for Hepatitis C with Epclusa is 12 weeks. This is based on clinical trials and the results of which showed that the majority of patients were able to achieve a sustained virologic response (SVR), meaning the virus was undetectable in their blood, within this time frame.
However, some patients may require a longer or shorter treatment duration, and the decision is typically made by the healthcare provider based on the specific needs of the patient.
Epclusa is a combination of two antiviral drugs (sofosbuvir and velpatasvir) and is used to treat all genotypes (1-6) of Hepatitis C. It is considered a highly effective treatment option for many patients with Hepatitis C.
There are several other treatment options for Hepatitis C, including:
- Harvoni (ledipasvir and sofosbuvir)
- Maviret (glecaprevir and pibrentasvir)
- Zepatier (elbasvir and grazoprevir)
- Vosevi (sofosbuvir, velpatasvir, and voxilaprevir)
The choice of treatment will depend on various factors, including the genotype of the Hepatitis C virus, the presence of any coexisting medical conditions, and the overall health of the individual. Your healthcare provider will work with you to determine the best treatment plan based on your specific needs.